RUNX1 and neoplasm: This recent evidence suggests that blocking the transcriptional activity of RUNX1 in vivo could simultaneously reduce tumor growth and increase its sensitivity to drugs, as well as weaken the pro-tumorigenic effect of the microenvironment.